白蛋白作为纳米药物递送载体的独特性,Molecular Pharmaceutics

当前位置： X-MOL 学术 › Mol. Pharmaceutics › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

白蛋白作为纳米药物递送载体的独特性
Molecular Pharmaceutics ( IF 4.5 ) Pub Date : 2021-03-31 , DOI: 10.1021/acs.molpharmaceut.1c00046
Alessandra Spada _{1,

2,

3} , Jaber Emami _{3,

4} , Jack A Tuszynski _{1,

2} , Afsaneh Lavasanifar ₃

Affiliation

白蛋白因其独特的特性而成为纳米医学中一种有吸引力的载体。首先，它是血浆中含量最丰富的蛋白质，具有高度的生物相容性、生物降解性、非免疫原性和临床应用安全性。其次，白蛋白的化学结构和构象允许与许多不同的药物相互作用，有可能保护它们在体内免于消除和代谢，从而改善它们的药代动力学特性。最后，白蛋白可以与许多患病组织和细胞中过度表达的受体相互作用，为主动靶向疾病部位提供独特的功能，而无需向纳米载体添加特定的配体。因此，白蛋白的特点是血清半衰期延长了约 19 天，具有促进药物半衰期延长和靶向递送的潜力。因此，本文重点介绍白蛋白作为疏水性药物纳米药物递送载体的重要性，利用该纳米载体的被动和主动靶向潜力。特别关注突破性的 NAB 技术，强调了 Nab-紫杉醇 (Abraxane) 与紫杉醇的溶剂型制剂相比的优势，即，临床环境中的 CrEL-紫杉醇 (Taxol)。最后，描述了白蛋白在携带抗癌化合物中的作用，特别关注目前正在进行临床试验的基于白蛋白的制剂。这篇文章阐明了内源性物质（如白蛋白）作为药物递送系统的能力，表明药物载体在生物系统中的药物性能中的重要性，并强调了使用这种药物递送的未来可能的趋势系统。

"点击查看英文标题和摘要"

The Uniqueness of Albumin as a Carrier in Nanodrug Delivery

Albumin is an appealing carrier in nanomedicine because of its unique features. First, it is the most abundant protein in plasma, endowing high biocompatibility, biodegradability, nonimmunogenicity, and safety for its clinical application. Second, albumin chemical structure and conformation allows interaction with many different drugs, potentially protecting them from elimination and metabolism in vivo, thus improving their pharmacokinetic properties. Finally, albumin can interact with receptors overexpressed in many diseased tissues and cells, providing a unique feature for active targeting of the disease site without the addition of specific ligands to the nanocarrier. For this reason, albumin, characterized by an extended serum half-life of around 19 days, has the potential of promoting half-life extension and targeted delivery of drugs. Therefore, this article focuses on the importance of albumin as a nanodrug delivery carrier for hydrophobic drugs, taking advantage of the passive as well as active targeting potential of this nanocarrier. Particular attention is paid to the breakthrough NAB-Technology, with emphasis on the advantages of Nab-Paclitaxel (Abraxane), compared to the solvent-based formulations of Paclitaxel, i.e., CrEL-paclitaxel (Taxol) in a clinical setting. Finally, the role of albumin in carrying anticancer compounds is depicted, with a particular focus on the albumin-based formulations that are currently undergoing clinical trials. The article sheds light on the power of an endogenous substance, such as albumin, as a drug delivery system, signifies the importance of the drug vehicle in drug performance in the biological systems, and highlights the possible future trends in the use of this drug delivery system.

更新日期：2021-05-03

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南